12-Week INH-RPT Regimen for Treatment of Latent TB Infection
In December 2011, the Centers for Disease Control and Prevention (CDC) published recommendations for an additional option for the treatment of latent TB infection (LTBI) in some individuals. This new regimen consists of 12 weekly doses of isoniazid (INH) and rifapentine (RPT). It is intended for use in certain high-risk patients and must be administered as Directly Observed Therapy (DOT) by local health departments. Links to CDC materials about this regimen are listed below.
MDH will supply medications for this regimen through its free TB medications program for patients who meet eligibility criteria and for whom a specific plan is in place to provide monthly physical examinations at a clinic and DOT by the local health department. Local health departments in Minnesota may vary in their ability to provide this service.
- Eligibility Criteria for the Use of the 12-week INH-RPT LTBI Regimen (PDF: 89KB/1 page)
Lists recommended situations based on CDC criteria in which the 12-week LTBI treatment regimen may be considered.
- MDH Recommendations for the Use of the 12-week Isoniazid and Rifapentine Regimen for the Treatment of Latent Tuberculosis Infection (PDF: 82KB/3 pages)
MDH recommendations and special considerations for the use, administration, and patient monitoring for the 12-week LTBI treatment regimen.
- MDH TB Medications Program
MDH’s program for providing TB medications free-of-charge for Minnesota residents who are receiving treatment for LTBI or active TB disease.
- Recommendations for Use of an Isoniazid-Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection
Published in the Centers for Disease Control and Prevention's MMWR:60(48);1650-1653. Attention: Non-MDH link
- Webinar: Using the 12-Week INH-RPT Regimen for the Treatment of Latent TB Infection (LTBI)
Slides for webinar (439KB/40 pages)
MDH webinar for local public health nurses, approximately 50 minutes long, that explains the 12-week isoniazid (INH) and rifapentine (RPT) LTBI treatment regimen and describes recommended situations in which it may be considered. The webinar also outlines how local health departments in Minnesota can request INH-RPT from the MDH TB Medications program.
- CDC Issues Recommendations on Use of New Treatment Option for Latent TB infection
Press release from the Centers for Disease Control and Prevention. Attention: Non-MDH link
- Treatment Options for Latent Tuberculosis Infection
Brief overview of treatment for latent TB infection from the Centers for Disease Control and Prevention. Attention: Non-MDH link
- New Treatment Regimen for Latent Tuberculosis Infection
Video of Dr. Kenneth Castro discussing CDC guidelines for the use of a new regimen for the treatment of persons with LTBI. Attention: Non-MDH link
- TBeat: HNTC Newsletter
Frequently Asked Questions issued by Heartland National TB Center on the INH-RPT regimen. They can be found in the newsletter dated March 2012, Volume 7 #1. Attention: Non-MDH link
